Coronary Artery Disease Pipeline Key Players, Therapies, Pre-Clinical Products Report 2022

Coronary Artery Disease Pipeline Insights, 2022″ report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Coronary Artery Disease (CAD) market. A detailed picture of the Coronary Artery Disease (CAD) pipeline landscape is provided, which includes the disease overview and Coronary Artery Disease (CAD) treatment guidelines.

Coronary Artery Disease Overview
Coronary artery disease (CAD), or coronary heart disease (CHD) is a major cause of death in developed, as well as developing countries, is a medical condition that arises when coronary arteries are not able to supply oxygen and nutrients to heart muscles due to possible blockage (atherosclerosis), disease or damage in arteries.

Get Access to a Free Copy of Our Latest Sample Report @ https://www.delveinsight.com/sample-request/coronary-artery-disease-cad-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Coronary Artery Disease Types
Coronary artery disease is broadly divided into three types:
• Obstructive coronary artery disease, with narrowed or blocked vessels.
• Non-obstructive coronary artery disease, with arteries that inappropriately constrict or malfunction after branching into tiny vessels, or are squeezed by the overlying heart muscle.
• Spontaneous coronary artery dissection (SCAD), in which the layers of the artery suddenly split.

List of Coronary Artery Disease Companies includes-
• Amgen
• AstraZeneca
• Celecor Therapeutics
• XyloCor Therapeutics, and others

Coronary Artery Disease Therapies
• XC 001
• Zalunfiban
• AZD-5718
• Evolocumab, and others

Coronary Artery Disease Symptoms
Coronary Artery Disease symptoms can range from shortness of breath to chest pain of varying intensity. This kind of chest pain is called angina. It is usually associated with a feeling of constriction or anxiety, and it may extend into the arms, back of the neck, back, upper abdomen or jaw. These symptoms are most often triggered by physical exertion because the heart muscle needs more oxygen then. They occur if too little blood flows through the coronary arteries.

Coronary Artery Disease Risk Factors
• Smoking
• Diabetes
• Hypertension
• Obesity
• Homocystinuria
• Hyperuricemia
• Psychosocial stress

Coronary Artery Disease Diagnosis
Coronary Artery Disease can be diagnosed in several ways. Patients with documented (prior) MI or coronary artery revascularization (either with PCI or CABG) have CHD. Moreover, the presence of typical angina suggests a clinical diagnosis of CHD, but most often requires confirmation by additional diagnostic tests, such as coronary angiography. However, this test is an invasive and relatively costly procedure associated with a low, yet definite, risk of an adverse event. Coronary angiography is most often performed following an abnormal stress test or in the setting of an acute coronary syndrome (unstable angina or heart attack) in individuals who are candidates for revascularization (either by PCI or CABG).

Coronary Artery Disease Treatment
Coronary angioplasty is also known as percutaneous coronary intervention, is a procedure which involves temporarily inserting and inflating a tiny balloon where the artery is clogged to enlarge the artery. Two antiplatelet drugs have been approved for the long-term treatment of CAD in Germany and other countries: Acetylsalicylic acid (ASA) and clopidogrel. Statins are medications that lower certain cholesterol levels in the blood (cholesterol-lowering drugs). Beta blockers lower the heart rate, which reduces the strain on the heart. They also reduce blood pressure. ACE inhibitors and angiotensin II antagonists (also known as sartans) are blood-pressure-lowering drugs. Coronary artery bypass grafting (CABG) is a type of heart surgery for patients with severe coronary heart disease (CHD).

Download Free Sample Report Now @ https://www.delveinsight.com/sample-request/coronary-artery-disease-cad-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Coronary Artery Disease Pipeline Report
The assessment part of the report embraces in-depth Coronary Artery Disease (CAD) commercial assessment and clinical assessment of the Coronary Artery Disease (CAD) pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Coronary Artery Disease (CAD) collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

Coronary Artery Disease Pipeline Development Activities
The report provides insights into:
• All of the companies that are developing therapies for the treatment of Coronary Artery Disease (CAD) with aggregate therapies developed by each company for the same.
• Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the Coronary Artery Disease (CAD)
• Coronary Artery Disease (CAD) key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of Coronary Artery Disease (CAD)

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university web sites and industry-specific third-party sources, etc.

Coronary Artery Disease Pipeline Report Scope
• The Coronary Artery Disease (CAD) report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Coronary Artery Disease (CAD) across the complete product development cycle, including all clinical and nonclinical stages.
• It comprises of detailed profiles of Coronary Artery Disease (CAD) therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
• Detailed Coronary Artery Disease (CAD) research and development progress and trial details, results wherever available, are also included in the pipeline study.
• Coverage of dormant and discontinued pipeline projects along with the reasons if available across Coronary Artery Disease (CAD).

Read Full Research Report @ https://www.delveinsight.com/report-store/coronary-artery-disease-cad-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of content
1. Report Introduction
2. Coronary Artery Disease (CAD)
3. Current Treatment Patterns
4. DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Late Stage Products (Phase-III)
7. Mid Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Discontinued Products
13. Product Profiles
14. Key Companies
15. Key Products
16. Dormant and Discontinued Products
17. Unmet Needs
18. Future Perspectives
19. Analyst Review
20. Appendix
21. Report Methodology

Connect with our Business Expert @ https://www.delveinsight.com/report-store/coronary-artery-disease-cad-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Contact Us
Yash
info@delveinsight.com

About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

This release was published on openPR.